S. Zeuzem

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
S. Zeuzem, Stefan Zeuzem
Publication record
129 papers · 7,858 citations · H-index 47

PAPERS

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
20237 citationsauthor #13
Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
20230 citationsauthor #7
Outcomes, clinical trajectories and risk factors of acute kidney injury (AKI) in critically-ill patients with liver cirrhosis
20230 citationsauthor #13
Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D
20230 citationsauthor #14
Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response
20230 citationsauthor #15
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients with prior failure to DAA treatment
20230 citationsauthor #9
From the Editor's Desk...
20231 citationsauthor #4
Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries.
202346 citationsauthor #4
Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial
20234 citationsauthor #11
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm
20230 citationsauthor #39
Most vulnerable HCV patient groups treated with direct acting antivirals achieve high response rates and gain quality of life-data from the German hepatitis C-registry (DHC-R)
20230 citationsauthor #10
Expanding epidemic of recently acquired HCV in HIV-coinfected patients over a period of 10 years
20234 citationsauthor #15
International Open Is a higher frequency of esophageal dilations more effective in treating benign esophageal strictures: a retrospective, multicenter study
20230 citationsauthor #10
Treatment of Non-Anastomotic Biliary Strictures after Liver Transplantation: How Effective Is Our Current Treatment Strategy?
20234 citationsauthor #16
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
202334 citationsauthor #19
Hepatitis D double reﬂex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
202310 citationsauthor #4
From the Editor's Desk...
20230 citationsauthor #4
Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses
20234 citationsauthor #14
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
202356 citationsauthor #15
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
202370 citationsauthor #7
Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients
20231 citationsauthor #18
Quadruple mutation GCAC1809-1812TTCT leads to a better prognosis by decreasing HBV-mediated fibrogenic activity
20230 citationsauthor #8
A conserved motif in the disordered linker of human MLH1 is vital for DNA mismatch repair and its function is diminished by a cancer family mutation
20236 citationsauthor #8
Bone Marrow Assessment in Liver Cirrhosis Patients with Otherwise Unexplained Peripheral Blood Cytopenia
20235 citationsauthor #8
Risk Factors and Role of Antibiotic Prophylaxis for Wound Infections after Percutaneous Endoscopic Gastrostomy
20232 citationsauthor #12
From the Editor's Desk...
20230 citationsauthor #4
Key role of phosphorylation sites in ATPase domain and Linker region of MLH1 for DNA binding and functionality of MutLα
20233 citationsauthor #3
Active Autophagy Is Associated with Favorable Outcome in Patients with Surgically Resected Cholangiocarcinoma
20232 citationsauthor #8
Fluorescence confocal microscopy on liver specimens for full digitization of transplant pathology
20235 citationsauthor #9
Interventional oncological treatment of hepatocellular carcinoma (HCC) - A single-center long-term evaluation of thermoablation techniques like LITT, MWA, and TACE in a multimodal application over 26 years.
20238 citationsauthor #6
Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease
20233 citationsauthor #15
Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
20232 citationsauthor #21
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
2023129 citationsauthor #23
Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos (t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial
20232 citationsauthor #7
Pathogenetic mechanisms and therapeutic approaches of acute-to-chronic liver failure.
202316 citationsauthor #29
Patients with liver cirrhosis and TIPS are prone to in-hospital falls
20230 citationsauthor #5
(N)one size fits all: Genotype-matched analysis of different disease phases of chronic hepatitis B virus infection
20230 citationsauthor #10
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.
2023259 citationsauthor #269
From the Editor's Desk...
20230 citationsauthor #4
From the Editor's Desk...
20231 citationsauthor #4
P582 Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure
20210 citationsauthor #6
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
20207 citationsauthor #1
Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg‐negative chronic HBV infection
201839 citationsauthor #11
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection].
2018191 citationsauthor #21
No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct‐acting antivirals for hepatitis C in a large real‐world cohort
201738 citationsauthor #7
Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis
201755 citationsauthor #4
The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis
201666 citationsauthor #4
The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection
201682 citationsauthor #7
Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients – authors' reply
20150 citationsauthor #3
Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis
2015110 citationsauthor #3
P0727 : Clinical utility of the artus HCV QS-RGQ assay for HCVRNA quantification
20150 citationsauthor #6
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection
201417 citationsauthor #10
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double‐blinded multicentre trial
201429 citationsauthor #5
Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
201447 citationsauthor #6
The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis
201413 citationsauthor #7
Severe 25‐hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma – a prospective cohort study
201478 citationsauthor #5
Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany
201324 citationsauthor #8
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta‐analysis
2012497 citationsauthor #10
Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease
20124 citationsauthor #21
New developments in HCV therapy
201244 citationsauthor #2
Title Page/Editorial Board
20120 citationsauthor #1
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin
201219 citationsauthor #1
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b
201248 citationsauthor #9
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
2011109 citationsauthor #9
Comparison of Envelope 2 CD81 binding regions in PBMC‐derived versus serum‐derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates
20113 citationsauthor #8
Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study.
201167 citationsauthor #9
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline].
2011189 citationsauthor #14
Long‐term effectiveness and cost‐effectiveness of antiviral treatment in hepatitis C
201044 citationsauthor #7
Prediction of nonSVR to therapy with pegylated interferon‐α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment
201012 citationsauthor #8
Efficacy and Safety of Sorafenib in Advanced Hepatocellular Carcinoma Under Daily Practice Conditions
201014 citationsauthor #8
Differentiation between Benign and Malignant Adrenal Mass using Contrast-Enhanced Ultrasound
201051 citationsauthor #12
Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy
2010109 citationsauthor #3
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
200976 citationsauthor #10
Real-time elastography and contrast-enhanced ultrasound for the assessment of thyroid nodules.
2009125 citationsauthor #11
Expert opinion on the treatment of patients with chronic hepatitis C
2009236 citationsauthor #1
Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C
200931 citationsauthor #3
Frequent in‐frame somatic deletions activate gp130 in inflammatory hepatocellular tumors
200918 citationsauthor #2
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa‐2b combination therapy for chronic hepatitis C
2009215 citationsauthor #5
The German Hep-Net Acute Hepatitis C Cohort: Impact of Viral and Host Factors on the Initial Presentation of Acute Hepatitis C Virus Infection
200939 citationsauthor #12
Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy
200859 citationsauthor #9
Meta‐analysis: the outcome of anti‐viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
2008116 citationsauthor #6
Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon‐alpha 2a plus ribavirin
20085 citationsauthor #6
Neoadjuvant Treatment with Cetuximab, 5-Fluorouracil, Folinic Acid and Oxaliplatin in Unresectable Retroperitoneal Recurrent Colon Cancer
200811 citationsauthor #5
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection
200780 citationsauthor #7
Transarterielle Chemoembolisation (TACE) des hepatozellulären Karzinoms: Technik, Indikationsstellung und Ergebnisse
200754 citationsauthor #8
Review article: predicting response in hepatitis C virus therapy
200667 citationsauthor #4
Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity
200653 citationsauthor #1
The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation
200579 citationsauthor #5
13C‐methacetin breath test as liver function test in patients with chronic hepatitis C virus infection
200584 citationsauthor #4
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
200595 citationsauthor #17
Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Authors' reply
20050 citationsauthor #9
An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo
200468 citationsauthor #9
Nodular Regenerative Hyperplasia of the Liver: a Rare Differential Diagnosis of Cholestasis with Response to Ursodeoxycholic Acid
200322 citationsauthor #3
Frequency of the Amsterdam Criteria in a Regional German Cohort of Patients with Colorectal Cancer
20028 citationsauthor #13
TH1/TH2 Serum Cytokine Profiles and soluble TNF-Receptor Response in Patients with Chronic Hepatitis C during Recombinant Human Interleukin-12 (rHuIL-12) Treatment
20023 citationsauthor #5
Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
200150 citationsauthor #7
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.
2001305 citationsauthor #1
The kinetics of hepatitis C virus infection.
200121 citationsauthor #1
Activation of a cryptic splice site of PTEN and loss of heterozygosity in benign skin lesions in Cowden disease.
200123 citationsauthor #7
Comparative sequence analysis of the core‐ and NS5‐region of hepatitis C virus from tumor and adjacent non‐tumor tissue
200133 citationsauthor #2

TIMELINE

1991 6 citations

1994 66 citations

1995 86 citations

1996 715 citations

1997 312 citations

1998 1,496 citations

1999 167 citations

2000 326 citations

2001 454 citations

2002 11 citations

2003 22 citations

2004 68 citations

2005 258 citations

2006 120 citations

2007 134 citations

2008 191 citations

2009 740 citations

2010 230 citations

2011 368 citations

2012 612 citations

2013 24 citations

2014 184 citations

2015 110 citations

2016 148 citations

2017 93 citations

2018 230 citations

2020 7 citations

2021 0 citations

2023 684 citations

S. Zeuzem

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT